Patent · US Active

Treating male senescence

US11090307B2 · kind B2 · utility

2Cited by

0References

20Claims

0Family size

Assignee

National Institute of Biological Sciences, Beijing · CN

Inventors

Xiaodong Wang · Zhejiang, CN
Dianrong Li · Zhejiang, CN
Lingjun Meng · Beijing, CN
Zhiyuan Zhang · Beijing, CN

Key dates

Filing date	Oct 18, 2019
Grant date	Aug 17, 2021
Priority date	—
Expiry date	Dec 19, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P15/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides methods of treating male reproductive senescence comprising administering to a male in need thereof a necroptosis inhibitor, including inhibitors of RIP1, RIP3 or MLKL. The invention also provides pharmaceutical compositions comprising a necroptosis inhibitor and a second different drug for treating male senescence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.